Brokerage morning meeting highlights: Now is the right time for AI healthcare layout.

In today's Brokerage morning meeting, Sinolink proposed that the layout of AI in healthcare is timely; HTSC expressed a bullish outlook on the product upgrades and commercial breakthroughs of AI applications in China by 2025; China Securities Co.,Ltd. believes that the turning point in the IDC Industry is approaching, and a new cycle is expected to begin.

cls.cn19:26 ET

Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.

In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.

Zhitong FinanceFeb 13 22:11 ET

Express News | Sihuan Pharma - Repurchased 10 Mln Shares of Co at Average Price of HK$0.5723 per Share

ReutersFeb 11 06:35 ET

On February 11, SIHUAN PHARM (00460.HK) spent 5.72 million Hong Kong dollars to repurchase 10 million shares.

Gelonghui reported on February 11 that SIHUAN PHARM (00460.HK) announced that on February 11, it spent 5.72 million Hong Kong dollars to repurchase 10 million shares, with the repurchase price ranging from 0.57 to 0.58 Hong Kong dollars per share.

Gelonghui FinanceFeb 11 06:04 ET

Sihuan Pharmaceutical: Decline in Generic Drug Business Weighed on Results >0460.HK

Dow JonesFeb 3 16:56 ET

Sihuan Pharmaceutical Sees 2024 Rev CNY1.8B >0460.HK

Dow JonesFeb 3 16:56 ET